Aaby, P; Martins, CL; Garly, ML; Andersen, A; Fisker, AB; Claesson, MH; Ravn, H; Rodrigues, A; Whittle, HC; Benn, CS (2014) Measles vaccination in the presence or absence of maternal measles antibody: Impact on child survival. Clinical infectious diseases. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciu354

Downloaded from: http://researchonline.lshtm.ac.uk/1726167/

DOI: 10.1093/cid/ciu354

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary table 1. Causes of death by verbal autopsy according to maternal antibody level at time of measles vaccination in Trial II

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Undetectable measles antibody level</th>
<th>Had maternal measles antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory infection</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhoea, diarrhoea and vomiting</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Malaria, fever and anaemia</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Traditional ceremony</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>(mongoloid child)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No information (family moved)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>11</td>
<td>4</td>
</tr>
</tbody>
</table>
Supplementary Figure 1: Trial diagrams for the two early two-dose measles vaccination trials.

**Trial I (1993-95)**

**Randomised to MV**
- N=150

- Had detectable maternal antibody: N=27
  - Moved: 0
  - MV at 9 mo: 27 (100%)
  - Died: 0

- Had no detectable maternal antibody: N=123
  - Moved: 6 (5%)
  - MV at 9 mo: 114 (93%)
  - Died: 3 (2%)

- Still in area: 17 (63%)
  - Moved: 10 (37%)
  - Died: 0

**Followed**

**Randomised to IPV**
- N=150

- Had detectable maternal antibody: N=23
  - Moved: 3 (13%)
  - MV at 9 mo: 20 (87%)
  - Died: 0

- Had no detectable maternal antibody: N=127
  - Moved: 6 (5%)
  - MV at 9 mo: 118 (93%)
  - Died: 3 (2%)

- Still in area: 49 (43%)
  - Moved: 52 (46%)
  - Died: 13 (11%)

**Outcomes 6 to 9 months**

**Outcomes 9 to 60 months**
Notes: MV=measles vaccine; mo=month